日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

An Analysis of the Gut Microbiota and Related Metabolites following PCSK9 Inhibition in Statin-Treated Patients with Elevated Levels of Lipoprotein(a)

对接受他汀类药物治疗的脂蛋白 a 水平升高患者进行 PCSK9 抑制后肠道菌群及相关代谢物的分析

Jose A Caparrós-Martín, Patrice Maher, Natalie C Ward, Montserrat Saladié, Patricia Agudelo-Romero, Stephen M Stick, Dick C Chan, Gerald F Watts, Fergal O'Gara

Lipoprotein(a) Particle Production as a Determinant of Plasma Lipoprotein(a) Concentration Across Varying Apolipoprotein(a) Isoform Sizes and Background Cholesterol-Lowering Therapy

脂蛋白(a)颗粒生成是不同载脂蛋白(a)亚型大小和背景降胆固醇治疗中血浆脂蛋白(a)浓度的决定因素

Dick C Chan, Gerald F Watts, Blai Coll, Scott M Wasserman, Santica M Marcovina, P Hugh R Barrett

Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism

PCSK9(前蛋白转化酶枯草溶菌素/Kexin 9 型)抑制剂和他汀类药物对餐后富含甘油三酯的脂蛋白代谢的比较影响

Dick C Chan, Gerald F Watts, Ransi Somaratne, Scott M Wasserman, Rob Scott, P Hugh R Barrett

Nonalcoholic fatty liver disease as the transducer of hepatic oversecretion of very-low-density lipoprotein-apolipoprotein B-100 in obesity

非酒精性脂肪性肝病是肥胖患者肝脏过度分泌极低密度脂蛋白-载脂蛋白 B-100 的传导媒介

Dick C Chan, Gerald F Watts, SengKhee Gan, Annette T Y Wong, Esther M M Ooi, P Hugh R Barrett